Compass Therapeutics Announces Issuance of Composition of Matter and Method Patents Covering Its Lead Immuno-oncology Candidate, CTX-471 – Business Wire

Compass Therapeutics Announces Issuance of Composition of Matter and Method Patents Covering Its Lead Immuno-oncology Candidate, CTX-471  Business Wire

Compass Therapeutics today announced that the U.S. Patent and Trademark Office issued three U.S. patents covering certain anti-CD137 antibodies.